Literature DB >> 2482226

Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements.

S M Hanly1, L T Rimsky, M H Malim, J H Kim, J Hauber, M Duc Dodon, S Y Le, J V Maizel, B R Cullen, W C Greene.   

Abstract

The Rex proteins of types I and II human T-cell leukemia viruses (HTLV-I, HTLV-II) are required for expression of the viral structural gene products, gag and env and, thus, are essential for the replication of these pathogenic retroviruses. The action of Rex is sequence specific, requiring the presence of a cis-acting Rex response element located in the 3' long terminal repeat. This element corresponds to a predicted RNA secondary structure and functions in an orientation-dependent but position-independent manner. Rex acts through this response element to stimulate the nuclear export of the unspliced or singly spliced viral mRNA species encoding the virion structural proteins that are normally excluded from the cytoplasm. Although the Rex proteins of HTLV-I and HTLV-II can also function via the related Rev response element present in the env gene of the type I human immunodeficiency virus (HIV-1), the analogous HIV-1 Rev protein is unable to act on the HTLV-I Rex response element. This nonreciprocal pattern of genetic complementation by Rex and Rev suggests that these viral trans-regulators may interact directly with their RNA response elements.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2482226     DOI: 10.1101/gad.3.10.1534

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  103 in total

1.  Anti-Rex aptamers as mimics of the Rex-binding element.

Authors:  S Baskerville; M Zapp; A D Ellington
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 2.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

3.  Posttranscriptional regulation by the human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type I Rex proteins through a heterologous RNA binding site.

Authors:  D McDonald; T J Hope; T G Parslow
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

4.  Specific binding of the human T-cell leukemia virus type I Rex protein to a short RNA sequence located within the Rex-response element.

Authors:  H P Bogerd; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

5.  Different sites of interaction for Rev, Tev, and Rex proteins within the Rev-responsive element of human immunodeficiency virus type 1.

Authors:  L Solomin; B K Felber; G N Pavlakis
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

6.  Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure.

Authors:  S M Holland; N Ahmad; R K Maitra; P Wingfield; S Venkatesan
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

Review 7.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

8.  An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300.

Authors:  R Harrod; Y Tang; C Nicot; H S Lu; A Vassilev; Y Nakatani; C Z Giam
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  Cellular protein modulates effects of human immunodeficiency virus type 1 Rev.

Authors:  Y Luo; H Yu; B M Peterlin
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding.

Authors:  J Katahira; T Ishizaki; H Sakai; A Adachi; K Yamamoto; H Shida
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.